Bases moleculares y celulares de enfermedades inflamatorias/autoinmunes
Hospital Universitario de la Princesa
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario de la Princesa (75)
2024
-
Does remission in systemic lupus erythematosus according to the 2021 DORIS definition match the treating rheumatologist's judgement?
Rheumatology (Oxford, England), Vol. 63, Núm. 1, pp. 72-78
2023
-
Central nervous system involvement in systemic lupus erythematosus: Data from the Spanish Society of Rheumatology Lupus Register (RELESSER)
Seminars in Arthritis and Rheumatism, Vol. 58
-
Gender biases in Spanish rheumatology: Perception and facts
Reumatologia Clinica, Vol. 19, Núm. 7, pp. 392-401
-
Occurrence of SARS-CoV-2 viremia is associated with genetic variants of genes related to COVID-19 pathogenesis
Frontiers in Medicine, Vol. 10
-
Pregnancy outcomes in 1869 pregnancies in a large cohort from the Spanish Society of Rheumatology Lupus Register (RELESSER)
Seminars in Arthritis and Rheumatism, Vol. 61
2022
-
Antimalarials exert a cardioprotective effect in lupus patients: Insights from the Spanish Society of Rheumatology Lupus Register (RELESSER) analysis of factors associated with heart failure
Seminars in Arthritis and Rheumatism, Vol. 52
-
Clinical characteristics and risk factors associated with lymphoma in patients with systemic lupus erythematosus: a nationwide cohort study
Rheumatology (Oxford, England), Vol. 62, Núm. 1, pp. 217-224
-
Genetic LGALS1 Variants Are Associated with Heterogeneity in Galectin‐1 Serum Levels in Patients with Early Arthritis
International Journal of Molecular Sciences, Vol. 23, Núm. 13
-
VIP/VPAC Axis Expression in Immune-Mediated Inflammatory Disorders: Associated miRNA Signatures
International journal of molecular sciences, Vol. 23, Núm. 15
2021
-
Do all antiphospholipid antibodies confer the same risk for major organ involvement in systemic lupus erythematosus patients?
Clinical and Experimental Rheumatology, Vol. 39, Núm. 3, pp. 555-563
-
Efficacy and safety of switching Jak inhibitors in rheumatoid arthritis: An observational study
Clinical and Experimental Rheumatology, Vol. 39, Núm. 3, pp. 453-455
-
Relevance of gastrointestinal manifestations in a large Spanish cohort of patients with systemic lupus erythematosus: what do we know?
Rheumatology (Oxford, England), Vol. 60, Núm. 11, pp. 5329-5336
-
The neuropeptide vip limits human osteoclastogenesis: Clinical associations with bone metabolism markers in patients with early arthritis
Biomedicines, Vol. 9, Núm. 12
2020
-
"There is something you must see": breaking down the remission concept in rheumatoid arthritis from a rheumatologist's perspective
Clinical and experimental rheumatology, Vol. 38, Núm. 1, pp. 82-87
-
A clinical approach for the use of VIP axis in inflammatory and autoimmune diseases
International Journal of Molecular Sciences, Vol. 21, Núm. 1
-
Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality
Lupus, Vol. 29, Núm. 12, pp. 1556-1565
-
Associated factors to serious infections in a large cohort of juvenile-onset systemic lupus erythematosus from Lupus Registry (RELESSER).
Seminars in Arthritis and Rheumatism, Vol. 50, Núm. 4, pp. 657-662
-
Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies
Autoimmunity Reviews, Vol. 19, Núm. 1
-
Differences in clinical manifestations and increased severity of systemic lupus erythematosus between two groups of Hispanics: European Caucasians versus Latin American mestizos (data from the RELESSER registry)
Lupus, Vol. 29, Núm. 1, pp. 27-36
-
Efficacy, safety and cost-effectiveness of a web-based platform delivering the results of a biomarker-based predictive model of biotherapy response for rheumatoid arthritis patients: A protocol for a randomized multicenter single-blind active controlled clinical trial (PREDIRA)
Trials, Vol. 21, Núm. 1